Warner Chilcott, which is 25 per cent owned by Elan, said its pre-tax loss narrowed to $2.0 million (€1.85 million) in the first quarter from a loss of $7.4 million in the same period last year, exceeding expectations. The company, which develops and markets prescription pharmaceutical products, said sales of its branded products reached a record $8.3 million, a 49 per cent increase. Overall, revenues totalled $21.0 million. Warner Chilcott said it had made progress in adding to its portfolio of branded products during the first quarter.